AGARWALEYE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 2.6
| Stock Code | AGARWALEYE | Market Cap | 14,455 Cr. | Current Price | 457 ₹ | High / Low | 568 ₹ |
| Stock P/E | 245 | Book Value | 61.8 ₹ | Dividend Yield | 0.00 % | ROCE | 5.94 % |
| ROE | 1.31 % | Face Value | 1.00 ₹ | DMA 50 | 445 ₹ | DMA 200 | 454 ₹ |
| Chg in FII Hold | -0.12 % | Chg in DII Hold | 0.05 % | PAT Qtr | 14.6 Cr. | PAT Prev Qtr | 4.95 Cr. |
| RSI | 59.8 | MACD | 4.17 | Volume | 64,113 | Avg Vol 1Wk | 85,061 |
| Low price | 327 ₹ | High price | 568 ₹ | PEG Ratio | 1.61 | Debt to equity | 0.30 |
| 52w Index | 53.8 % | Qtr Profit Var | 80.3 % | EPS | 1.75 ₹ | Industry PE | 48.0 |
📊 Analysis: Agarwal Eye (AGARWALEYE) shows weak fundamentals with ROE at 1.31% and ROCE at 5.94%, far below ideal levels for long-term compounding. Debt-to-equity at 0.30 indicates moderate leverage. Dividend yield of 0.00% offers no passive income. The P/E ratio of 245 is extremely stretched compared to the industry average of 48.0, suggesting severe overvaluation. PEG ratio of 1.61 indicates fair but slightly expensive growth valuation. PAT improved (₹4.95 Cr → ₹14.6 Cr), showing operational recovery, but overall earnings remain modest. RSI at 59.8 and MACD at 4.17 suggest neutral-to-positive momentum.
💰 Entry Price Zone: Ideal accumulation range is between ₹430–₹450 (near DMA 200 support). A deeper value zone lies around ₹370–₹380 if broader market correction occurs.
📈 Exit / Holding Strategy: For existing holders, maintain a short-term horizon (1–2 years) due to weak efficiency metrics and stretched valuations. Consider partial profit booking near ₹520–₹540 resistance. Exit strategy should be triggered if profitability stagnates or if valuations remain unsustainably high.
✅ Positive
- PAT improved from ₹4.95 Cr to ₹14.6 Cr.
- DII holdings increased slightly (+0.05%).
- Stock trading near DMA 50 and DMA 200, showing technical support.
⚠️ Limitation
- ROE (1.31%) and ROCE (5.94%) are very weak.
- P/E of 245 is far above industry average (48.0).
- Dividend yield of 0.00% offers no passive income.
- Book value of ₹61.8 is low compared to current price.
📉 Company Negative News
- FII holdings reduced (-0.12%), showing cautious foreign sentiment.
- Valuations remain extremely stretched compared to peers.
📈 Company Positive News
- PAT growth of 80.3% shows operational recovery.
- DII holdings increased slightly (+0.05%).
- Stock trading near support levels (DMA 50 & DMA 200).
🏭 Industry
- Industry P/E at 48.0, Agarwal Eye trades at a massive premium.
- Healthcare sector remains resilient but competitive, with demand for specialized services.
🔎 Conclusion
Agarwal Eye is financially stable with modest PAT recovery, but weak efficiency metrics and extremely stretched valuations make it unattractive for long-term compounding. Investors should avoid fresh long-term accumulation and instead consider short-term positions with profit booking near resistance levels.